MediciNova achieves target enrolment in SEANOBI-ALS study of MN-166

Trial StartMN-166Positive

AI Analysis

Summary

MediciNova announced it has achieved target enrollment of 200 patients in the SEANOBI-ALS clinical study evaluating MN-166 (ibudilast) for amyotrophic lateral sclerosis.

Clinical Trial Data

Patients

200

Outcome Details

Target enrollment of 200 patients achieved

Importance:5/10

Sentiment:

0.60

enrollmentSEANOBI-ALSALSibudilast

Related Companies

$CBDY $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on July 16, 2026 9:58 AM

Read Original